Last reviewed · How we verify
Current ART
At a glance
| Generic name | Current ART |
|---|---|
| Also known as | NP |
| Sponsor | The University of Texas Health Science Center, Houston |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy (PHASE1)
- Prevent TB: Choice Architecture for TPT Delivery (NA)
- Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-1 Research Participants
- A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen (PHASE4)
- Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC
- An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM (PHASE3)
- Advancing Reperfusion Therapy for Ischemic Stroke: Direct Transfer to Angiography Suite for Patients With Suspected Large Vessel Occlusion (NA)
- Gamified Healthy Lifestyle Training in Women Undergoing Assisted Reproductive Treatment (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Current ART CI brief — competitive landscape report
- Current ART updates RSS · CI watch RSS
- The University of Texas Health Science Center, Houston portfolio CI